Coromandel International — a quietly excellent fertilizer business digging itself a wider moat

The Pulse

Coromandel is India’s largest phosphatic-fertilizer marketer and a Murugappa Group company that has spent the last three years quietly turning itself from a fertilizer bagger into something more integrated and harder to dislodge — building a captive rock mine in Senegal, captive acid-and-power plants at Kakinada, and a fast-growing non-subsidy stack of crop protection, biologicals, nano fertilizers and farm retail. FY26 was, by the numbers, the biggest year it has ever had: record revenue of ₹31,827 crore (+30%) and record operating profit. Yet reported net profit actually fell to ₹1,898 crore, dragged not by the business but by one-off items, a near-doubling of depreciation as the capex wave switched on, and — most acutely — a late-year supply shock out of West Asia that sent ammonia and sulphur prices through the roof and crushed fertilizer margins. The company sits today at the awkward intersection of a strong long-term build and an ugly near-term squeeze, with the open question being how much of the cost spike the government’s subsidy regime will absorb. Management is unusually honest about all of it.

The Business

Strip away the jargon and Coromandel does two things. About 85% of revenue is fertilizer — mostly complex NPK grades and DAP sold to Indian farmers, where it is the country’s largest player with roughly 17.5% market share and a near-stranglehold in Andhra Pradesh and Telangana. The other ~15% is crop protection — pesticides and fungicides, where it is the world’s third-largest maker of mancozeb and a meaningful exporter, plus a small but high-value biologicals niche (it’s the world’s leading maker of azadirachtin, a neem-derived bio-pesticide).

What makes it more than a commodity fertilizer maker is a set of structural advantages competitors can’t easily copy. The most important is backward integration: most Indian fertilizer firms import their phosphoric acid and rock phosphate, leaving them at the mercy of a handful of global suppliers in what management bluntly calls an “oligopolistic” market. Coromandel has spent heavily to own its own supply — a 71.5%-owned rock mine in Senegal (now its largest single export source of rock) and, as of March 2026, a new acid complex at Kakinada that makes its own sulphuric and phosphoric acid and generates its own power. The pitch, repeated across every call, is that this improves margins “irrespective of the direction of prices” because it captures the conversion spread and removes a layer of dependence. Layered on top is a differentiation story — roughly 35% of fertilizer volume is in “unique grades” (specialty formulations rather than vanilla DAP), it’s the largest seller of single super phosphate, the clear leader in Nano DAP (~50% share), and it runs a farmer-facing network of retail stores, agronomists and even drone-spraying services that competitors largely don’t bother with. Think of it as a company trying to wrap a sticky services-and-specialty layer around a commodity core.

The numbers tell you this works. Return on capital sits at ~23% today — high for a regulated, subsidy-linked fertilizer business where the economics are usually capped — and operating margins, though thin at 10–11%, are strikingly stable year after year. That combination of thin-but-stable margins and high asset turns is what produces the strong returns.

How Management Thinks

The people running Coromandel come across, across four calls and three annual reports, as measured, candid and allergic to spin — a refreshing register for an Indian promoter-group company. MD & CEO S. Sankarasubramanian (elevated in FY25, part of a clean generational handover that also moved Arun Alagappan to Executive Chairman and the long-serving A. Vellayan to Chairman Emeritus) tends to open calls with a professorial walk through the monsoon, reservoir levels and policy backdrop before getting to results — the posture of an industry steward rather than a stock promoter. When quarters are bad, he says so: he openly conceded a market-share slip to 14%, a channel-inventory build, missing his own crop-protection growth target (“blamed weather, not execution”), and a ₹71 crore writedown on the Dhaksha drone bet that is “a bit ahead of time.”

The clearest tell came on the May 2026 call, when analysts pressed four separate times for guidance on fertilizer margins and he flatly refused — “every day is a new day… the situation is fluid.” Many managements would have offered a comforting number; the refusal reads as genuine uncertainty about how the government and the cost spike will play out, and it is more reassuring than a confident fib.

On capital allocation, the philosophy is consistent and sensible: security-first and payback-driven. Greenfield expansion is explicitly ruled out as uneconomic; growth comes from brownfield debottlenecking, bolt-on acquisitions (the NACL agrochem buy, where they installed their own man, ran a rights issue to retire expensive debt, and are nursing margins back up), and locking up raw-material supply upstream. They quantify paybacks unprompted (the Kakinada acid investment at 2–2.5 years) and refuse to chase spot economics — they were upfront that a gypsum-recycling JV “doesn’t play such a significant role in the overall economics” and wasn’t justified on gypsum prices. The balance sheet has historically been net cash; they are now deliberately re-levering (borrowings ₹780cr → ₹1,506cr) to fund roughly ₹3,000 crore of capex over two years, and they have cut the dividend payout from a third of profit to about 17% to retain cash for it. The one thing the cash-return toolkit conspicuously lacks is a buyback — there has never been one in the data.

Do the numbers back the words? Mostly, yes. They promised Kakinada would commission in Q4 FY26 and it did, on time. NACL is turning as advertised. The notable miss is the fertilizer margin guidance — the “₹5,000–5,500 per tonne” floor they confidently reiterated through late 2025 collapsed below ₹3,500 in the March quarter once the West Asia shock hit. That’s less a credibility failure than a reminder that the single biggest variable in this business is outside management’s control.

Where It’s Going

The whole story right now bends around one external event. A supply crisis in West Asia — shipping disruption through the Strait of Hormuz, plus outages — sent ammonia to ~$840–850 and sulphur to ~$800, far above year-ago levels. Those are the two key fertilizer inputs, and the government’s Kharif 2026 subsidy hike of just 10% does not cover the increase, especially with the rupee weak. So the near-term picture is genuinely tense: management is lobbying Delhi for additional cost-to-cost subsidy, holding strategic inventory, and will raise farmer prices only if a gap remains after the government responds. They’ve also flagged that trading (imported DAP) volumes will likely drop in the first half of FY27 simply because the material may not be available.

Against that headwind, the structural build keeps marching. Kakinada is expected at full capacity by mid-FY27, lifting fertilizer EBITDA per tonne toward ₹6,500 from a ~₹5,000 base once conditions normalize, worth roughly ₹400 crore a year. Senegal rock volumes are guided up 30–40%, a one-million-tonne NPK plant lands in Q3 FY27, and the non-subsidy engines are the real growth story — crop protection carried FY26 with profit up 55% at a ~19% margin, NACL is climbing back to 9–10% margins, Nano DAP and retail are both growing fast, and a longer-dated contract-manufacturing (CDMO) ambition won’t pay off until FY29 or later. The direction of travel management clearly wants is for the subsidy business to shrink as a share of profit (it’s already drifted from ~70% to 66% of EBITDA). The genuine risks to watch beyond the cost shock: a deteriorating working-capital cycle (debtor days have jumped from 19 to 49 and free cash flow collapsed from ₹2,030 crore to near zero in FY26), the rising debt that funds the build, and the permanent structural dependence on a single counterparty — the Government of India — for both subsidy policy and timely payment.

The Four Checks

1. Quality & moat (the gate). Pass — but a qualified pass. This is a genuinely good business with real, widening structural advantages: scale leadership in phosphatics, backward integration into captive rock and acid that most peers lack, a differentiated specialty/unique-grade mix, regional dominance in the South, and a farmer-facing distribution network that’s hard to replicate. The ~23% ROCE in a regulated commodity industry is the proof. But be honest about the shape of the moat — it’s a cost-and-distribution advantage inside a thin-margin, monsoon-cyclical, subsidy-regulated commodity, not pricing power. Real pricing power lives only in the smaller crop-protection and specialty layer. So: a good business digging a wider moat in a structurally hard industry, rather than a wide-moat compounder.

2. Returns on incremental capital & runway. ROCE is healthy at 22.8% but has stepped down from a 32–38% peak in FY21–23, and the recent capex wave (fixed assets tripled, ₹2,200cr → ₹6,790cr in three years) has so far coincided with lower returns and collapsing free cash flow — the new assets only just switched on and haven’t yet earned. Management’s thesis is that backward integration restores the spread (the ₹5,000 → ₹6,500/tonne uplift). The runway is real: India remains a large net importer of phosphatics, leaving volume headroom, and the non-subsidy stack has a long growth path. Read it as high base returns currently diluted by a capex-digestion phase, with a credible-but-unproven path back up — and a core whose incremental returns are ultimately capped by subsidy economics.

3. Capital allocation for the stage. Rational for where the business is. Returns are still well above the cost of capital, so reinvesting hard — into return-accretive backward integration, upstream security, and higher-margin non-subsidy lines — is the right call, and they’re funding it partly by cutting the dividend payout (33% → 17%), which is appropriate when reinvestment beats returning cash. Greenfield is correctly ruled out on returns; M&A is used with discipline. The one gap against this check’s preferred logic: no buyback, even with the stock near its 52-week low — defensible mid-build, but the cash-return muscle is untested.

4. Price. Fair-to-demanding, not cheap. At ₹1,812 the stock trades at ~26.7x trailing earnings and ~4.25x book, with a 0.63% dividend yield — and that’s on FY26 earnings that actually fell. For a business compounding profit at roughly 14% over a decade with ~23% ROCE, ~27x is a full multiple that prices in the quality premium and the backward-integration optionality rather than offering a margin of safety. If the integration thesis delivers and fertilizer margins normalize, forward earnings would make the multiple look more reasonable; if the West Asia squeeze lingers and subsidy support lags, the current price looks demanding. The market is valuing Coromandel as a quality compounder, not as the subsidy-cyclical it partly still is — which leaves little cushion if the near-term margin pressure persists. (Characterisation only — not a buy/sell call.)

Sources

• Concall transcripts read: Q1 FY26 (call 25 Jul 2025), Q2 FY26 (31 Oct 2025), Q3 FY26 (2 Feb 2026), Q4/FY26 (8 May 2026).
• Annual reports read: FY23, FY24, FY25 (trimmed high-signal sections).
• Snapshot: screener.in consolidated, fetched 2026-06-09 12:33 IST (logged-out public session).
• Research dumps: vault/Sources/Earnings/Coromandel International Ltd/ (per-source digests + cleaned PDFs; not published).
• Gaps to flag: the FY24 and FY23 annual-report extracts were skewed toward governance/risk notes — the full MD&A narrative, consolidated P&L lines and dividend/buyback specifics were largely absent from those trims, so FY23–FY24 figures lean on the segment-information notes. All four concalls and the FY25 report came through cleanly.